Merck Beats Quarterly Sales Expectations as Keytruda Fuels Growth

Why It Matters

Keytruda’s growth offsets short‑term acquisition costs, reinforcing Merck’s revenue engine while the company works to diversify beyond its flagship immunotherapy before patent expiry.

Key Takeaways

• Keytruda sales hit $8 billion, up 12% YoY.
• Merck shares rose up to 5% in pre‑market trading.
• $3.62‑per‑share charge reflects Cidara acquisition cost.
• New injectable Keytruda contributed $128 million to sales.
• CEO cites over 20 product launches with blockbuster potential.

Pulse Analysis

Keytruda remains the cornerstone of Merck’s portfolio, now the world’s top‑selling prescription drug with $8 billion in quarterly revenue. The 12% year‑over‑year growth reflects expanding indications and the recent launch of an injectable version, which alone added $128 million. This momentum not only beat consensus forecasts but also underscores the drug’s resilience amid a competitive oncology landscape, where biosimilars and next‑generation immunotherapies are gaining traction.

The $3.62‑per‑share charge tied to the Cidara Therapeutics acquisition signals Merck’s strategic push into antiviral and infectious‑disease markets. While the short‑term impact widened the quarterly loss, the deal adds a pipeline of novel candidates that could diversify earnings beyond oncology. Coupled with more than 20 late‑stage products slated for launch, Merck is betting on a broader therapeutic footprint to sustain growth once Keytruda’s patent protection expires later in the decade.

Investors are weighing the trade‑off between immediate earnings pressure and long‑term value creation. The stock’s pre‑market rally to +5% reflects confidence that the company’s pipeline depth and disciplined capital allocation will offset the looming patent cliff. Analysts are watching data from Merck’s advanced candidates slated for 2026‑27, which could cement its position as a diversified biopharma leader rather than a single‑product powerhouse.